Takeda takes control of Shire
8th Jan 2019 07:39
(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.
Read moreTakeda shareholders approve £46bn Shire takeover
5th Dec 2018 08:00
(Sharecast News) - Takeda Pharmaceutical shareholders have approved its £46bn takeover of London-listed pharmaceutical group Shire.
Read moreSunday newspaper round-up: US-China, Brexit, Royal Mail, Barclays, Shire
2nd Dec 2018 11:57
(Sharecast News) - China and the United States have agreed to halt additional tariffs as both nations engage in new trade negotiations with the goal of reaching an agreement within 90 days, the White House said on Saturday after talks between President Donald Trump and President Xi Jinping in Argentina. - Sunday Telegraph
Read moreShire gets EC approval for hereditary angioedema jab
30th Nov 2018 07:23
(Sharecast News) - Shire's injectable treatment for hereditary angioedema (HAE) has been cleared for launch in European, having enjoyed early success in the US.
Read moreEU clears Takeda's Shire acquisition on divestment condition
20th Nov 2018 14:34
(Sharecast News) - The European Commission has cleared Takeda Pharmaceutical's £46bn acquisition of Shire, subject to the divestment of a bowel disease drug under development by Shire.
Read moreShire sales remain solid, Takeda deal 'on track'
1st Nov 2018 12:09
(Sharecast News) - Shire Pharmaceuticals, the subject of a $62bn takeover by Japan's Takeda, said its focus on rare diseases had offset foreign exchange weakness and boosted third-quarter profits.
Read moreTakeda proposes selling off Shire drug to gain merger clearance
29th Oct 2018 12:19
(Sharecast News) - Takeda Pharmaceuticals may need to sell off one of Shire's pipeline drugs in order to gain European regulatory clearance for the agreed $62bn takeover.
Read moreTakeda proposes selling off Shire drug to gain merger clearance
29th Oct 2018 12:19
(Sharecast News) - Takeda Pharmaceuticals may need to sell off one of Shire's pipeline drugs in order to gain European regulatory clearance for the agreed $62bn takeover.
Read moreShire hopes to get green light for US Flexbumin manufacture
25th Oct 2018 16:21
(Sharecast News) - Shire on Thursday filed a submission to the US food and drug administration to gain approval to manufacture Flexbumin at its new facility in the state of Georgia.
Read moreShire's lanadelumab gets one step closer to European approval
19th Oct 2018 14:38
(Sharecast News) - Rare disease-focussed biotechnology company Shire announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorisation of 'lanadelumab' injection, for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Read moreShire gets approval for hereditary angioedema treatment in Japan
21st Sep 2018 07:19
(Sharecast News) - Rare disease specialist Shire announced on Friday that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for its 'FIRAZYR' icatibant injection, for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE.
Read moreShire gains as takeover approved by China
14th Sep 2018 09:15
(Sharecast News) - Japan's Takeda Pharmaceutical has received regulatory approval from China for its $62bn takeover of London-listed Shire.
Read moreTakada eyeing potential Shire asset sales to pay down debt
13th Sep 2018 10:56
(Sharecast News) - Takeda Pharmaceutical may try and sell Shire's dry-eye drug once it completes the $62bn takeover purchase of the UK-listed biotech, according to a report on Thursday.
Read moreShire gets EC marketing authorisation for 'VEYVONDI' treatment
12th Sep 2018 07:22
(Sharecast News) - Rare diseases specialist Shire announced on Wednesday that the European Commission has granted marketing authorisation for 'VEYVONDI', for the treatment of bleeding events and the treatment and prevention of surgical bleeding in adults with von Willebrand disease, when desmopressin treatment alone is ineffective or not indicated.
Read moreShire buys Swiss plasma firm sanaplasma for undisclosed sum
6th Sep 2018 10:52
(Sharecast News) - Pharmaceuticals giant Shire on Thursday said it had bought Switzerland's sanaplasma AG for an undisclosed sum.
Read more